M. Aris

发表

Origin of normal and malignant melanocytes

M. Aris, Bioquímica Molecular, 2009 .

Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.

M. Roberti, M. Bianchini, E. Levy, 2012, Human pathology.

Inoculation Site from a Cutaneous Melanoma Patient Treated with an Allogeneic Therapeutic Vaccine: A Case Report

J. Mordoh, M. M. Barrio, A. Bravo, 2015, Front. Immunol..

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report

P. Yankilevich, E. Levy, J. Mordoh, 2018, Front. Immunol..

Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges

L. Kremer, M. Vela, J. A. Garcia-Sanz, 2015, Front. Immunol..

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

M. M. Barrio, M. Aris, Mariana Aris, 2015, Front. Immunol..

Lessons from Cancer Immunoediting in Cutaneous Melanoma

J. Mordoh, M. M. Barrio, M. Aris, 2012, Clinical & developmental immunology.

Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood

M. Nielsen, J. Mordoh, M. M. Barrio, 2019, Front. Immunol..

An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases

J. Pardo, J. Mordoh, G. Cueto, 2022, Frontiers in Immunology.

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

E. Levy, J. Mordoh, M. M. Barrio, 2017, Front. Immunol..

Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report

J. Mordoh, M. M. Barrio, A. Mordoh, 2023, BMC Medical Genomics.

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

J. Mordoh, M. M. Barrio, M. Aris, 2017, Front. Immunol..

MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.

Marina Colombo, M. Bianchini, J. Mordoh, 2012, The Journal of investigative dermatology.

Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine.

J. Mordoh, J. Arriaga, M. M. Barrio, 2012, Cryobiology.

Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF

P. Yankilevich, M. Nielsen, J. Mordoh, 2020, Frontiers in Immunology.

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.

M. Roberti, M. Bianchini, E. Levy, 2012, Human pathology.

Abstract CT118: A randomized phase II study of the CSF-470 therapeutic vaccine plus BCG plus rhGM-CSF versus IFN-α2b in cutaneous melanoma patients stages IIB, IIC and III

E. Levy, J. Mordoh, M. M. Barrio, 2015 .

Vacuna terapéutica CSF-470 para melanoma cutáneo

J. Mordoh, M. M. Barrio, M. Aris, 2013 .

A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A retrospective study

J. Mordoh, Mora Amat, M. M. Barrio, 2023, Oncology research.

Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge

J. Mordoh, M. M. Barrio, M. Aris, 2010 .